Evidence map›Paper›PMID 30289054›Full record

ArticleVirulence2018

Assessing the function of pneumococcal neuraminidases NanA, NanB and NanC in in vitro and in vivo lung infection models using monoclonal antibodies.

Philipp Janesch, Harald Rouha, Adriana Badarau, Lukas Stulik, Irina Mirkina, Marisa Caccamo, Katharina Havlicek, Barbara Maierhofer, Susanne Weber, Karin Groß and 9 more

Open access · goldAbstract read
In one paragraph

Article in Virulence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. The dynamic interplay betweenFrontiers in cellular and infection microbiology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Combining the In Silico and In Vitro Assays to IdentifyPharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies.Frontiers in cellular and infection microbiology · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Genomic Characteristics of InvasiveBioinformatics and biology insights · 2020
    Article
  12. Sialidases FromFrontiers in cellular and infection microbiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Philipp Janescha Arsanis Biosciences , Vienna , Austria.
Harald Rouhaa Arsanis Biosciences , Vienna , Austria.
Adriana Badaraua Arsanis Biosciences , Vienna , Austria.
Lukas Stulika Arsanis Biosciences , Vienna , Austria.
Irina Mirkinaa Arsanis Biosciences , Vienna , Austria.
Marisa Caccamoa Arsanis Biosciences , Vienna , Austria.
Katharina Havliceka Arsanis Biosciences , Vienna , Austria.
Barbara Maierhofera Arsanis Biosciences , Vienna , Austria.
Susanne Webera Arsanis Biosciences , Vienna , Austria.
Karin Großa Arsanis Biosciences , Vienna , Austria.
Jacqueline Steinhäusera Arsanis Biosciences , Vienna , Austria.
Manuel Zerbsa Arsanis Biosciences , Vienna , Austria.
Cecilia Vargaa Arsanis Biosciences , Vienna , Austria.
Ivana Dolezilkovaa Arsanis Biosciences , Vienna , Austria.
Sabine Maiera Arsanis Biosciences , Vienna , Austria.
Gerhild Zaunera Arsanis Biosciences , Vienna , Austria.
Nels Nielsonb Adimab LLC , Lebanon , NH , USA.ORCID 0000-0001-9920-8052
Christine A Powera Arsanis Biosciences , Vienna , Austria.
Eszter Nagya Arsanis Biosciences , Vienna , Austria.
Adimab (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Streptococcus pneumoniae isolates express up to three neuraminidases (sialidases), NanA, NanB and NanC, all of which cleave the terminal sialic acid of glycan-structures that decorate host cell surfaces. Most research has focused on the role of NanA with limited investigations evaluating the roles of all three neuraminidases in host-pathogen interactions. We generated two highly potent monoclonal antibodies (mAbs), one that blocks the enzymatic activity of NanA and one cross-neutralizing NanB and NanC. Total neuraminidase activity of clinical S. pneumoniae isolates could be inhibited by this mAb combination in enzymatic assays. To detect desialylation of cell surfaces by pneumococcal neuraminidases, primary human tracheal/bronchial mucocilial epithelial tissues were infected with S. pneumoniae and stained with peanut lectin. Simultaneous targeting of the neuraminidases was required to prevent desialylation, suggesting that inhibition of NanA alone is not sufficient to preserve terminal lung glycans. Importantly, we also found that all three neuraminidases increased the interaction of S. pneumoniae with human airway epithelial cells. Lectin-staining of lung tissues of mice pre-treated with mAbs before intranasal challenge with S. pneumoniae confirmed that both anti-NanA and anti-NanBC mAbs were required to effectively block desialylation of the respiratory epithelium in vivo. Despite this, no effect on survival, reduction in pulmonary bacterial load, or significant changes in cytokine responses were observed. This suggests that neuraminidases have no pivotal role in this murine pneumonia model that is induced by high bacterial challenge inocula and does not progress from colonization as it happens in the human host.

Indexed as

A549 CellsAnimalsAntibodies, BacterialAntibodies, MonoclonalBacterial ProteinsDisease Models, AnimalEpithelial CellsFemaleHost-Pathogen InteractionsHumansLungMiceNeuraminidasePneumonia, PneumococcalPolysaccharidesStreptococcus pneumoniaeAntibodies, BacterialAntibodies, MonoclonalBacterial ProteinsNanC protein, Streptococcus pneumoniaeNeuraminidasePolysaccharideshost-pathogen interactionshuman and mouse lung infection modelsmonoclonal antibodiesneuraminidases NanA NanB NanCStreptococcus pneumoniae

Identifiers

PMID30289054
PMCPMC6177239
OpenAlexW2895609536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.